Texas Cardiac Arrhythmia Research Foundation
Austin, Texas, 78758, United States
NCT Number: NCT00729911
1. To determine if catheter-based atrial fibrillation (AF) ablation is superior to Amiodarone treatment for symptomatic persistent/permanent AF in ICD/CRTD patients with an impaired left ventricular function. 2. Hypothesis: AF ablation is better than Amiodarone for subjects with symptomatic persistent or permanent AF and impaired LV function in terms of recurrence of AF, quality of life, 6-minute walk distance, EF and total number of hospitalizations.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Austin, Texas, 78758, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The exclusion criteria are:
Radio-frequency catheter ablation of atrial fibrillation
Taken orally on a daily basis.
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Time frame: 1 year
Texas Cardiac Arrhythmia Research Foundation
Other
Ablation vs. Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05750953
Cardiovascular Diseases, Colon Rectal Cancer
Stavanger, Rogaland, Norway
View Trial DetailsNCT02061319
Cardiovascular Diseases, Heart Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT06576050
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT04113109
Cardiovascular Diseases, Heart Diseases
Nashville, Tennessee, United States
View Trial Details